Name: Fmoc-L-Lys(Boc-Cys(Trt))-OH
SKU: FAA9315
Availability: InStock

Grouped product items

Qty

Packing unit

Price

SKU

Availability

1 g

$375.00

FAA9315.0001

5 g

$1,500.00

FAA9315.0005

description

Bicyclic peptides have high potential as next generation pharmaceuticals, e.g., to disrupt the difficult to target interactions between proteins. For controlled cyclization, selective reactivities are required. Our 1,2-aminothiol and 1,3-thiazole building blocks yield the ideal combination for this purpose, and, in addition, are compatible with SPPS. Besides, when used N-terminally, 1,2-aminothiols are useful for connecting peptide fragments by native chemical ligation (NCL).

references

Improving the stability of thiol–maleimide bioconjugates via the formation of a thiazine structure; I. N. Gober, R. Sharan, M. Villain; J. Pept. Sci. 2023; 29(10): e3495. https://doi.org/10.1002/psc.3495

Biocompatible and Selective Generation of Bicyclic Peptides; S. Ullrich, J. George, A. E. Coram, R. Morewood, C. Nitsche; Angew. Chem. Int. Ed. 2022; 61(43): e202208400. https://doi.org/10.1002/anie.202208400

A biocompatible stapling reaction for in situ generation of constrained peptides; R. Morewood, C. Nitsche; Chem. Sci. 2021; 12: 669-674. https://doi.org/10.1039/D0SC05125J

A Flexible Synthesis of 68Ga-Labeled Carbonic Anhydrase IX (CAIX)-Targeted Molecules via CBT/1,2-Aminothiol Click Reaction; K.-T. Chen, K. Nguyen, C. Ieritano, F. Gao, Y. Seimbille; Molecules 2019; 24(1): 23. https://doi.org/10.3390/molecules24010023

Early-Stage Incorporation Strategy for Regioselective Labeling of Peptides using the 2-Cyanobenzothiazole/1,2-Aminothiol Bioorthogonal Click Reaction; K.-T. Chen, C. Ieritano, Y. Seimbille; ChemistryOpen 2018; 7(3): 256-261. https://doi.org/10.1002/open.201700191

Two bifunctional desferrioxamine chelators for bioorthogonal labeling of biovectors with zirconium-89; F. Gao, C. Ieritano, K.-T. Chen, G. M. Dias, J. Rousseau, F. Benard, Y. Seimbille; Org. Biomol. Chem. 2018; 16: 5102-5106. https://doi.org/10.1039/C8OB01434E

Bifunctional PEGylated exenatide-amylinomimetic hybrids to treat metabolic disorders: an example of long-acting dual hormonal therapeutics; C. Sun, J. L. Trevaskis, C. M. Jodka, S. Neravetla, P. Griffin, K. Xu, Y. Wang, D. G. Parkes, B. Forood, S. S. Ghosh; J Med Chem. 2013; 56(22): 9328-41. https://doi.org/10.1021/jm401418s

Cell permeable ITAM constructs for the modulation of mediator release in mast cells; J. Kuil, M. J. E. Fischer, N. J. de Mol, R. M. J. Liskamp; Org. Biomol. Chem. 2011; 9: 820-833. https://doi.org/10.1039/C0OB00441C

Synthesis and use of a pseudo-cysteine for native chemical ligation; D. A. Alves, D. Esser, R. J. Broadbridge, A. P. G. Beevers, C. P. Chapman, C. E. Winsor, J. R. Betley; J Pept Sci. 2003; 9(4):221-228. https://doi.org/10.1002/psc.448

Platform for Orthogonal N-Cysteine-Specific Protein Modification Enabled by Cyclopropenone Reagents; A. Istrate, M. Geeson, C. Navo, B. Sousa, M. Marques, R. Taylor, T. Journeaux, S. Oehler, M. Mortensen, M. Deery, A. Bond, F. Corzana, G. Jiménez-Osés, G. Bernardes; JAmChemSoc. 2022; 144: 10396-10406. https://doi.org/10.1021/jacs.2c02185

Recent advances in N- and C-terminus cysteine protein bioconjugation; R. Spears, V. Chudasama; CurrOpinChemBiol. 2023; 75: 102306. https://doi.org/10.1016/j.cbpa.2023.102306

* Disclaimer

We refer to our general terms and conditions.
All information contained in our webshop is compiled to the best of our knowledge.
Prices and product availability are subject to change and require reconfirmation. Please contact us for further information.